156 related articles for article (PubMed ID: 18445662)
1. Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy.
Colao A; Pivonello R; Galderisi M; Cappabianca P; Auriemma RS; Galdiero M; Cavallo LM; Esposito F; Lombardi G
J Clin Endocrinol Metab; 2008 Jul; 93(7):2639-46. PubMed ID: 18445662
[TBL] [Abstract][Full Text] [Related]
2. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study.
Colao A; Auriemma RS; Galdiero M; Lombardi G; Pivonello R
J Clin Endocrinol Metab; 2009 Oct; 94(10):3746-56. PubMed ID: 19622615
[TBL] [Abstract][Full Text] [Related]
3. Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly.
Colao A; Cuocolo A; Marzullo P; Nicolai E; Ferone D; Florimonte L; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 1999 Jan; 84(1):17-23. PubMed ID: 9920056
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular consequences of early-onset growth hormone excess.
Colao A; Spinelli L; Cuocolo A; Spiezia S; Pivonello R; di Somma C; Bonaduce D; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 2002 Jul; 87(7):3097-104. PubMed ID: 12107207
[TBL] [Abstract][Full Text] [Related]
5. Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors.
Ronchi CL; Varca V; Beck-Peccoz P; Orsi E; Donadio F; Baccarelli A; Giavoli C; Ferrante E; Lania A; Spada A; Arosio M
J Clin Endocrinol Metab; 2006 Jan; 91(1):121-8. PubMed ID: 16263816
[TBL] [Abstract][Full Text] [Related]
6. Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure.
Puig-Domingo M; Resmini E; Gomez-Anson B; Nicolau J; Mora M; Palomera E; MartĂ C; Halperin I; Webb SM
J Clin Endocrinol Metab; 2010 Nov; 95(11):4973-8. PubMed ID: 20739382
[TBL] [Abstract][Full Text] [Related]
7. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study.
Lombardi G; Colao A; Marzullo P; Biondi B; Palmieri E; Fazio S;
J Endocrinol Invest; 2002 Dec; 25(11):971-6. PubMed ID: 12553557
[TBL] [Abstract][Full Text] [Related]
8. Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study.
Colao A; Auriemma RS; Galdiero M; Cappabianca P; Cavallo LM; Esposito F; Grasso LF; Lombardi G; Pivonello R
J Clin Endocrinol Metab; 2009 Feb; 94(2):528-37. PubMed ID: 19001517
[TBL] [Abstract][Full Text] [Related]
9. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis.
Maison P; Tropeano AI; Macquin-Mavier I; Giustina A; Chanson P
J Clin Endocrinol Metab; 2007 May; 92(5):1743-7. PubMed ID: 17311857
[TBL] [Abstract][Full Text] [Related]
10. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
Plöckinger U; Quabbe HJ
Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
[TBL] [Abstract][Full Text] [Related]
11. Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues.
Sherlock M; Fernandez-Rodriguez E; Alonso AA; Reulen RC; Ayuk J; Clayton RN; Holder G; Sheppard MC; Bates A; Stewart PM
J Clin Endocrinol Metab; 2009 Apr; 94(4):1255-63. PubMed ID: 19158203
[TBL] [Abstract][Full Text] [Related]
12. Cardiac mass and function, carotid artery intima-media thickness, and lipoprotein levels in growth hormone-deficient adolescents.
Lanes R; Gunczler P; Lopez E; Esaa S; Villaroel O; Revel-Chion R
J Clin Endocrinol Metab; 2001 Mar; 86(3):1061-5. PubMed ID: 11238486
[TBL] [Abstract][Full Text] [Related]
13. GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment.
Colao A; Terzolo M; Bondanelli M; Galderisi M; Vitale G; Reimondo G; Ambrosio MR; Pivonello R; Lombardi G; Angeli A; degli Uberti EC
Clin Endocrinol (Oxf); 2008 Oct; 69(4):613-20. PubMed ID: 18410555
[TBL] [Abstract][Full Text] [Related]
14. Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly.
Theodoropoulou M; Tichomirowa MA; Sievers C; Yassouridis A; Arzberger T; Hougrand O; Deprez M; Daly AF; Petrossians P; Pagotto U; Beckers A; Stalla GK
Int J Cancer; 2009 Nov; 125(9):2122-6. PubMed ID: 19637311
[TBL] [Abstract][Full Text] [Related]
15. Glucose homeostasis in patients with acromegaly treated with surgery or somatostatin analogues.
Tzanela M; Vassiliadi DA; Gavalas N; Szabo A; Margelou E; Valatsou A; Vassilopoulos C
Clin Endocrinol (Oxf); 2011 Jul; 75(1):96-102. PubMed ID: 21521267
[TBL] [Abstract][Full Text] [Related]
16. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy.
Colao A; Baldelli R; Marzullo P; Ferretti E; Ferone D; Gargiulo P; Petretta M; Tamburrano G; Lombardi G; Liuzzi A
J Clin Endocrinol Metab; 2000 Jan; 85(1):193-9. PubMed ID: 10634386
[TBL] [Abstract][Full Text] [Related]
17. Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center.
Bacigaluppi S; Gatto F; Anania P; Bragazzi NL; Rossi DC; Benvegnu G; Nazzari E; Spaziante R; Giusti M; Ferone D; Zona G
Endocrine; 2016 Mar; 51(3):524-33. PubMed ID: 25982150
[TBL] [Abstract][Full Text] [Related]
18. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
[TBL] [Abstract][Full Text] [Related]
19. The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly.
De Marinis L; Bianchi A; Mazziotti G; Mettimano M; Milardi D; Fusco A; Cimino V; Maira G; Pontecorvi A; Giustina A
Pituitary; 2008; 11(1):13-20. PubMed ID: 17987389
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA.
De Marinis L; Bianchi A; Fusco A; Cimino V; Mormando M; Tilaro L; Mazziotti G; Pontecorvi A; Giustina A
Pituitary; 2007; 10(3):227-32. PubMed ID: 17484056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]